Pyxis Oncology, Inc. (PYXS) stock
PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.81+0.13 (+7.74%)
Close on Nov 20, 2026Market cap $150.97MP/E –Yield –
Pyxis Oncology revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Pyxis Oncology's revenue for the twelve months ending Dec 31, 2025 was $13.86M, down 14.2% year over year. For fiscal 2025 it was $13.86M, down 14.2% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.86M | -14.2% |
| FY2024 | Dec 31, 2024 | $16.15M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $11.04M | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $2.82M | -82.5% |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $16.15M | – |
See a number that looks wrong?